cardiovascular toxicity

cardiovascular toxicity

[¦kärd·ē·ō¦vas·kyə·lər tak′sis·əd·ē]
(medicine)
The adverse effects on the heart or blood systems which result from exposure to toxic chemicals.
References in periodicals archive ?
Health effects from exposure to chemicals found in burn pits may include cancer, neurological effects, reproductive effects, respiratory toxicity, and cardiovascular toxicity.
With longer survival, cancer patients are now subject to the cardiovascular effects of aging as well as potential cardiovascular toxicity from modern cancer agents.
As reported previously, the FDA now requires that all new drugs approved for diabetes rule out cardiovascular toxicity rather than simply showing the agent lowers HbA1c levels.
Cardiac toxicity of local anesthetics: Cardiovascular toxicity produces changes in cardiac conduction, impairment of contractility and myocardial metabolic changes.
The reality is that trastuzumab is an effective medicine for treating breast cancer, but the risk of cardiovascular toxicity is underrated, explains Juan Carlos Plana, MD, co-director of Cleveland Clinic's Cardio-Oncology Center.
1 It's clear that cardiovascular toxicity occurs more frequently than hepatoxicity.
Kim JT, Jung CW, Lee KH 2004 The effect of insulin on the resuscitation of bupivacaine-induced severe cardiovascular toxicity in dogs Anesthesia & Analgesia 99 (3) 728-33
1136) assessed the impacts of load-related differences in DEE composition on models of inflammation, susceptibility to infection, and cardiovascular toxicity.
The administration of epinephrine at high doses (animal models) during the resuscitation maneuvers, together with Lipid Emulsions (LE) for managing cardiovascular toxicity due to bupivacaine, showed no benefits in recovery and suggests that this combination will prevent the reversal of bupivacaine toxicity (35).
Cardiovascular Toxicity of Selected Chemotherapy Agents Acute Coronary Heart Failure Hypertension Syndromes QTc Prolongation Anthracyclines Bevacizumab Fluorouracil Arsenic trioxide Trastuzumab Sorafenib Bevacizumab Depsipeptide Lapatinib Sunitinib Sorafenib Sunitinib Alemtuzumab VDAs * VDAs Dasatinib VDAs * Vascular disrupting agents Source: Dr.
The potential cardiovascular toxicity of these dementia drugs may be under-appreciated by clinicians, Park-Wyllie adds.
The search for less toxic, long-acting LAs was prompted by fatalities associated with the cardiovascular toxicity of bupivacaine.